Company: WHWK
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001628280-25-023932
Chunk: 242

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 242
---
 sales, net$7,145 $5,353 Total revenue7,145 5,353 Operating expenses  Selling, general and administrative12,815 10,620 Research and development8,788 13,593 Cost of goods sold760 652 Total operating expenses22,363 24,865 Loss from operations(15,218)(19,512)Other income (expense)Gain on sale of business87,443 — Foreign exchange loss— (1)Interest income791 1,282 Interest expense— (58)Total other income (expense), net88,234 1,223 Net income (loss)$73,016 $(18,289)Other comprehensive income (loss):Unrealized loss on investments, net of tax(15)(35)Comprehensive income (loss)73,001 (18,324)Net income (loss) per share:Basic$1.84 $(0.68)Diluted$1.83 $(0.68)Weighted average shares outstanding:Basic39,640,826 26,980,698 Diluted39,932,539 26,980,698 

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

Table of Contents

WHITEHAWK THERAPEUTICS, INC.

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands, including share amounts)

(Unaudited)

For the Three Months Ended March 31, 2025Stockholders' EquityCommon StockAdditional Paid-In Capital Accumulated Other Comprehensive IncomeAccumulated Deficit Total SharesPar ValueBalance at December 31, 202424,681 $2 $385,114 $16 $(332,654)$52,478 Share-based compensation expense— — 1,680 — — 1,680 Issuance of common stock upon exercise of warrants426 — — — — — Issuance of common stock upon exercise of stock options22 — 21 — — 21 Issuance of common stock in conjunction with vesting of restricted stock units63 — — — — — Private placement, net of transaction costs21,592 2 94,546 — — 94,548 Unrealized loss on investments, net of tax— — — (15)—